Clever Leaves (NASDAQ:CLVR) and Avenue Therapeutics (NASDAQ:ATXI) Financial Contrast

Institutional & Insider Ownership

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Avenue Therapeutics and Clever Leaves”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38 million	($0.94)	-0.59
Clever Leaves	$17.42 million	0.00	-$17.90 million	($12.36)	0.00

Avenue Therapeutics has higher earnings, but lower revenue than Clever Leaves. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avenue Therapeutics and Clever Leaves’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Clever Leaves	N/A	N/A	N/A

Volatility & Risk

Avenue Therapeutics has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 4212.86, suggesting that its share price is 421,186% more volatile than the S&P 500.

Summary

Avenue Therapeutics beats Clever Leaves on 5 of the 9 factors compared between the two stocks.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.